Adam Smith, a House of Representatives member representing Washington's 9th congressional district, discusses the state of U.S. healthcare and pharma.
Adam Smith, a House of Representatives member representing Washington's 9th congressional district, chats with Grant Playter, associate editor, to discuss the state of U.S. healthcare and pharma. Topics of discussion include Adam's memoir and own struggles with the healthcare system, balancing the competing demands of innovation and pricing, and the role of the judicial system with regards to FDA oversight.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.